Navigation Links
NeoStem Acquires Amorcyte, a Clinical Stage Cardiovascular Disease Cell Therapy Company
Date:10/17/2011

g from bone marrow and traveling to the damaged region of the heart following an AMI. Treatment with  AMR-001 involves infusion of an active population of these cells directly into a patient's heart via an intra-coronary catheter six to eleven days after an AMI (i.e., after the "hot" or inflammatory phase) and as such complements the body's natural rescue mechanism for those cells that face hypoxic stress (i.e., oxygen deprivation) as a result of an increased workload.

NeoStem believes AMR-001 stands alone in its ability to claim all of the following attributes:

  • a confirmed mechanism of action
  • access to a cGMP (current good manufacturing practices) facility
  • an established dose that exceeds the threshold for biological activity
  • use of autologous cells that have no risk of rejection and are capable of integrating and providing local support, potentially for a prolonged period of time as demonstrated in pre-clinical animal experiments
  • cells that are not expanded, thereby eliminating the potential concerns associated with such expansion, and
  • an issued patent with composition of matter, methods and processes claims with long remaining life.

"We are very much encouraged by the Phase 1 trial results and look forward to moving AMR-001 forward toward commercialization through NeoStem," said Dr. Andrew L. Pecora, Chief Medical Officer of NeoStem and Chief Scientific Officer of Amorcyte. "Through NeoStem's preclinical VSEL™ (very small embryonic-like stem cell) platform, the Phase 1-ready autoimmune disease product candidates of its Athelos subsidiary, and now through AMR-001, NeoStem seeks to fulfill the promise that an individual's own cells hold the potential to both heal and transform the way medicine is delivered."

Dr. Robin L. Smith, Chairman and CEO of NeoStem said, "The closing of our acquisition of Amorcyte represents a leap for
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Suzanne Somers, Renowned Author, Medical Advocate, and Official Spokesperson for NeoStem, Inc., Inspires the Audience on The Ellen Degeneres Show
2. NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.
3. NeoStem, Inc. to Enter the Regenerative Medicine Market in Asia
4. NeoStem Completes $500,000 Private Placement With Strategic Investor
5. NeoStems New York City Adult Stem Cell Collection Center Has Opened and Begun Collections
6. NeoStem Receives Notice of Noncompliance from NYSE Alternext US
7. NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
8. NeoStem Expands Stem Cell Collection Center Network Into New Jersey Led by Leading Plastic Surgeon and Anti-Aging Authority
9. NeoStem Completes $11 Million Private Placement Financing to Support Expansion Activities in China, Further Development of NeoStems VSEL Technology and Advancement of Medical Tourism Initiatives
10. NeoStem, Inc. Announces Agreement With Progenitor Cell Therapy, LLC
11. NeoStem Obtains Exclusive Worldwide License for Innovative Stem Cell Technology and Applications to Heal Chronic Wounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... VANCOUVER , Oct. 22, 2014 /PRNewswire/ - iCo ... ICOTF), today announced next steps for its Oral ... findings from its in vitro work ... therapy.  iCo now plans to complete pre clinical ... an initial Phase 1A clinical trial, utilizing approximately ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The ... (Medication Dispensing Systems, Packaging and Labeling Systems, Table-top ... Automation) - Global Forecasts & Trends to 2019” ... and opportunities in North America, Europe, Asia-Pacific, and ... 101 market tables and 30 figures spread through ...
(Date:10/20/2014)... 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... Q3 orders to $5.8 million and provides a good start to ... North America and one in the ... projects at record levels," said Peter Bruijns , President & ... end of Q3 than they have been for any complete year ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... has often been called "a game of inches," but biology ... a few nanometers can determine the fate of a cell ... cancerous. Scientists with the U.S. Department of Energy (DOE),s Lawrence ... better way to study the impact of spatial patterns on ...
... Calif., Nov. 1, 2011 Epitomics, Inc., a ... has received a Notice of Allowance from the ... Method for Identifying Differentially Expressed Proteins (application 10/705,109). ... differentially expressed proteins in cell samples using libraries ...
... DIEGO, Nov. 1, 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: ... will present at the 20th Annual Credit Suisse Healthcare ... Time (7:00 AM Pacific Time). (Logo:   ... the presentation will be accessible on the Investors page ...
Cached Biology Technology:Berkeley Lab scientists develop new tool for the study of spatial patterns in living cells 2Berkeley Lab scientists develop new tool for the study of spatial patterns in living cells 3
(Date:10/15/2014)... assess the pandemic risk from strains of influenza virus ... allow ourselves to become complacent that the most substantial ... scientists. , Influenza pandemics arise when a new virus ... widespread immunity – spreads in the human population. There ... years, the worst of which – the 1918 Spanish ...
(Date:10/15/2014)... to an unexpected extent. The outbreak does not follow ... shows a new disease dynamic in regions, where it ... German National Academy of Sciences Leopoldina, acatech – the ... of the German Academies of Sciences and Humanities have ... In the statement the academies call for the following ...
(Date:10/15/2014)... be awarded the 44th Rosenstiel Award for Distinguished Work ... research exploring the mechanisms of genomic instability and its ... is the second alumnus to win the Rosenstiel Award; ... 2003. , Alt is the Charles A. Janeway Professor ... School and an investigator at the Howard Hughes Medical ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... Scientists from Hungary, Germany and the U.K. have discovered that ... the active ingredient in marijuana (THC), but these play ... on "endocannabinoids" just published online in, and scheduled for the ... could lead to new drugs that treat skin conditions ranging ...
... Fla. -- A Florida State University faculty member ... class of cancer-killing drugs is attracting worldwide attention ... assistant professor of chemical and biomedical engineering at ... Engineering, is using high-powered computers to determine how ...
... University have found that quantum dot nanoparticles can penetrate ... into potential workplace concerns for healthcare workers or individuals ... research on potential biomedical applications of the tiny nanoparticles. ... different sizes, shapes and surface coatings do not penetrate ...
Cached Biology News:FSU researcher using computers to hone cancer-fighting strategies 2Study shows quantum dots can penetrate skin through minor abrasions 2
... Biosearch Technologies has been at the ... accelerate the discovery and application of ... FRET probes and primers or 100 ... applications, Biosearch can meet your most ...
Cultrex 3D Culture Matrix Rat Collagen I....
UNIVERSAL SCORECARD DNA, 1 EA. * Category: Reagents/Consumables....
Cultrex 3D Culture Matrix Laminin I....
Biology Products: